SCHEMBL6303149

SCHEMBL6303149

CC(=O)Nc1ccccc1Sc1ccc(C(=O)NC2CN3CCC2CC3C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 2/20 0.50
TDP1 Q9NUW8 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
LMNA P02545 3/20 0.41
ATM Q13315 2/20 0.41
MAPT P10636 6/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 5/20 0.40
HPGD P15428 1/20 0.40
GLA P06280 1/20 0.40
SLC6A9 P48067 1/20 0.39
BLM P54132 1/20 0.39
HTT P42858 1/20 0.39
POLB P06746 1/20 0.38
HTR3E A5X5Y0 1/20 0.38
HTR3B O95264 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6306928 0.87 CHRNA7 (0.52) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL6310867 0.87 CHRNA7 (0.53) CHRNA7ATMMEN1KMT2AHTT
SCHEMBL6305133 0.86 CHRNA7 (0.53) CHRNA7L3MBTL1ATMMEN1KMT2A
SCHEMBL6310069 0.86 CHRNA7 (0.53) CHRNA7LMNAATMMAPTMEN1
SCHEMBL6306069 0.86 CHRNA7 (0.53) CHRNA7ATMMEN1KMT2AHTT
SCHEMBL6881259 0.85 CHRNA7 (0.69) CHRNA7TDP1L3MBTL1ATMMEN1
SCHEMBL6303422 0.85 CHRNA7 (0.68) CHRNA7ATMMEN1KMT2AALDH1A1
SCHEMBL6303326 0.85 CHRNA7 (0.62) CHRNA7TDP1L3MBTL1ATMMAPT
SCHEMBL6303499 0.84 CHRNA7 (0.51) CHRNA7HTR3EHTR3BALOX15TSHR
SCHEMBL6303275 0.84 CHRNA7 (0.51) CHRNA7HTR3EHTR3BALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236279-A1 Substituted-aryl compounds for treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US claimed
US-6852716-B2 Substituted-aryl compounds for treatment of disease PFIZER INC (US) 2005-02-08 US disclosed
EP-1480977-A2 SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-12-01 EP disclosed
US-20030236279-A1 Substituted-aryl compounds for treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed
WO-2003070728-A2 AZABICYCLO-SUBSTITUTED BENZOYLAMIDES AND THIOAMIDES FOR TREATMENT OF CNS-RELATED DISORDERS PHARMACIA & UPJOHN COMPANY (US) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236279-A1 Substituted-aryl compounds for treatment of disease NAT1, CYP7A1, CYP7B1 CHRNA7 2937/4885TDP1 2467/4885L3MBTL1 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.